1 week Ago By ABMN Staff
Prudential Financial Inc. purchased a new position in ADC Therapeutics SA ( NYSE:ADCT – Free Report ) in the fourth quarter, Holdings Channel.com reports.
The firm purchased 17,430 shares of the company’s stock, valued at approximately $35,000. A number of other large investors have also recently made changes to their positions in ADCT. Kazazian Asset Management LLC purchased a new stake in ADC Therapeutics in the fourth quarter worth approximately $26,000.
Sei Investments Co. purchased a new position in shares of ADC Therapeutics in the 4th quarter worth $46,000. LPL Financial LLC bought a new stake in shares of ADC Therapeutics in the fourth quarter worth $50,000.
SG Americas Securities LLC grew its holdings in shares of ADC Therapeutics by 35.6% in the fourth quarter. SG Americas Securities LLC now owns 36,140 shares of the company’s stock worth $72,000 after acquiring an additional 9,483 shares during the period.
Finally, Intech Investment Management LLC increased its position in ADC Therapeutics by 195.7% during the fourth quarter. Intech Investment Management LLC now owns 38,435 shares of the company’s stock valued at $76,000 after acquiring an additional 25,437 shares during the last quarter.
41.10% of the stock is currently owned by institutional investors. Analyst Ratings Changes Several research analysts have issued reports on ADCT shares.
Cantor Fitzgerald reissued an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Guggenheim dropped their price objective on shares of ADC Therapeutics from $10.00 to $7.
00 and set a “buy” rating on the stock in a report on Monday, March 31st. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of ADC Therapeutics in a report on Monday, March 31st.
Finally, Stephens lifted their price target on shares of ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th.
Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, ADC Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.75.
ADC Therapeutics Stock Up 8.5 % NYSE ADCT opened at $1.22 on Friday.
ADC Therapeutics SA has a 52 week low of $1.05 and a 52 week high of $5.17.
The company has a market capitalization of $120.39 million, a P/E ratio of -0.51 and a beta of 1.
55. The stock’s 50-day moving average price is $1.55 and its 200-day moving average price is $2.
11. ADC Therapeutics ( NYSE:ADCT – Get Free Report ) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.
29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06.
The firm had revenue of $19.00 million for the quarter, compared to analysts’ expectations of $19.01 million.
Research analysts anticipate that ADC Therapeutics SA will post -1.69 EPS for the current year. ADC Therapeutics Profile ( Free Report ) ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Featured Stories Want to see what other hedge funds are holding ADCT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for ADC Therapeutics SA ( NYSE:ADCT – Free Report ). Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
